Clinically we found that, in a large cohort of PDAC and NSCLC clinical specimens, the integrated high expression levels of ENAH/AXL/GAS6 positively correlate with poor prognosis (Fig 7A and B; Appendix Fig S12) providing a novel predictive signature in PDAC and NSCLC progression. The gene discussed is ENAH; the disease is non-small cell lung carcinoma.